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ABSTRACT
Objective: The study aims to evaluate the plasma trace element status in beta-thalassemia trait (BTT) patients and demonstrate the correlation 
between trace elements and hemoglobin (Hb)-A1, HbA2, and HbF.
Methods: The study population consisted of 20 normal individuals and 40 patients with BTT aged between 25 and 55 years of both the sex. 
Hemoglobin variant analysis was performed in blood samples using cation exchange high-performance liquid chromatography. Patients were labeled 
as beta-thalassemia trait only if they had HbA2 >3.5% or HbF >2.0%. Plasma zinc was estimated by atomic absorption spectrometry, copper by 
bathocuproine disulfonate method, and iron by ferrozine method spectrophotometrically. Data were analyzed statistically by Student’s t -test and 
Pearson’s correlation using software SPSS version 20. p<0.05 was considered statistically significant.
Results: Plasma zinc and copper decreased significantly in BTT patients compared to healthy controls. There was an apparent decrease in plasma 
iron in these patients. Degree of decline in zinc (p<0.001) was much greater than that of copper (p<0.04). Moreover, there was significant elevation 
of copper-zinc ratio and iron-zinc ratio (p<0.001) in BTT patients compared to controls. Both HbA1 and HbA2 correlated positively with both copper 
and iron. Interestingly, HbF showed negative correlation with all the three trace elements in BTT patients.
Conclusion: The study highlights marked deficiency of plasma trace elements, hence, the need for periodic assessment and prompt administration 
of these micronutrients to reduce the complications in BTT patients. Further, ratios are more valuable markers in the determination of trace element 
status than individual elements.
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INTRODUCTION
Beta-thalassemia trait (BTT) is the most common single-gene inherited 
hemoglobinopathy in India with no gender discrimination. Among all 
the health problems in India, though the burden of hemoglobinopathies 
is significant, little attention has been given compared to malnutrition 
and other communicable diseases [1]. In beta-thalassemia, there is 
reduced production of beta-globin chains and increased synthesis of 
alpha and gamma chains. Increased alpha chains make the developing 
erythrocytes more fragile, leading to ineffective erythropoiesis, early 
damage, and anemia. Some of the patients may exhibit other symptoms 
such as impaired immune status, osteoporosis, and infections [2]. 
Deficiency of various micronutrients such as minerals and vitamins 
adds to the complications in these patients. Trace elements, namely iron, 
copper, and zinc, are required for heme biosynthesis. Copper plays a key 
role in several enzymatic reactions in RBC and its deficiency interferes 
with iron transport and therefore heme synthesis. Zinc is another trace 
element that is essential for cell-mediated immunity, activation of ALA 
dehydratase, and general growth [3]. Most of the trace element studies 
have been done on beta-thalassemia major patients and data are scarce 
on trait patients. Hence, our study aims to evaluate the plasma trace 
elements and demonstrate the correlation between trace elements and 
HbA1, HbA2, and HbF in BTT patients.
METHODS
The study population consisted of 20 normal individuals and 
40 patients with BTT aged between 25 and 55 years of both the sex. 
Random blood samples were collected in EDTA vacutainers and 
centrifuged at 3000 g for 10 min, plasma separated was used for the 
estimation of zinc by atomic absorption spectrometry and copper by 
bathocuproine disulfonate method where cuprous ions react with 
bathocuproine disulfonate to give a red-colored product [4]. Plasma 
iron was estimated by ferrozine method, in which ferrous ions formed 
by reduction using ascorbate combines with ferrozine to produce 
colored complex which is then measured spectrophotometrically [5]. 
Hemoglobin variant analysis was performed in blood samples using 
cation exchange high-performance liquid chromatography. Patients 
were labeled as beta-thalassemia trait only if they had HbA2 > 3.5% 
or HbF> 2.0%. Patients with anemia (Hb <14.0 g% in males and 
<12.0 g% in females) with no evidence of “nutritional deficiency,” renal 
or hepatic derangement, or chronic infection were considered for the 
study. None of the participants had taken mineral supplements before 
blood sampling. The study was approved by the institutional ethical 
committee and informed consent was taken from all the patients. Data 
were analyzed statistically by Student’s t-test and Pearson’s correlation 
using software SPSS version 20. p<0.05 was considered statistically 
significant.
RESULTS
Hemoglobin A1 level was significantly lower with concomitant increase 
in HbA2 and HbF in BTT patients compared to normal individuals 
(Table 1). There was an apparent decrease in iron values in BTT 
patients and the decrease in zinc and copper in BTT patients were 
statistically significant compared to healthy individuals. Degree of 
decline in zinc level (p<0.001) was much greater than that of copper 
(p<0.04) (Table 2). Further, there was a marked elevation in iron-zinc 
ratio and copper-zinc ratio (p<0.001) in BTT compared to controls. 
There was an insignificant negative correlation between zinc and 
different hemoglobins. Both HbA1 and HbA2 correlated positively with 
both copper and iron. Interestingly, HbF showed negative correlation 
with all the three trace elements in BTT patients (Table 3).
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DISCUSSION
Trace elements play a key role in metabolism within erythrocytes by 
participating in heme biosynthesis and other enzymatic reactions. 
BTT is a common heterozygous hemoglobinopathy characterized by 
hypochromia, microcytosis, and low-grade hemolysis [6]. Deficiency of 
trace elements like zinc is implicated in immune dysfunction. Moreover, 
impaired immune function is one of the salient features of BTT. Thus, 
alterations in these essential minerals seem to be related to different 
clinical complications associated with BTT.
The present study demonstrated a significant decrease in both copper 
and zinc in plasma of BTT patients compared to healthy controls. 
In accordance with our study, thalassemia major patients on iron 
chelation therapy and Jordanian thalassemia patients also exhibited 
decreased plasma copper and zinc [7,8]. However, thalassemic natives 
of Iran showed high copper but low plasma zinc [9]. In contrast, plasma 
copper remained normal in thalassemia major children but high in 
adult patients [10,11]. Increase in copper level has been attributed to 
recurrent infections in thalassemia major patients. Decreased plasma 
zinc in adult thalassemia major patients was also true for thalassemia 
minor patients as noted in our results. Decrease in plasma zinc may be 
due to increased excretion of zinc in urine released from hemolyzed red 
cells and due to malabsorption. Deficiency of zinc both in erythrocytes 
and plasma was a common feature of other hemoglobinopathies such as 
sickle cell disease and Hb E [12,13]. Further, copper and zinc deficiency 
may lead to a significant decline in erythrocyte membrane SOD, leading 
to increased oxidative stress and decreased RBC survival time [14]. 
Sickle cell anemia patients treated with zinc showed improvement 
both in skeletal growth and immune status [15]. Interestingly, zinc 
correlated negatively with all types of hemoglobins. Further, BTT 
patients exhibited marked elevation in copper-zinc ratio than individual 
elements in the present study, highlighting the fact that this ratio may 
be a more valuable indicator of imbalance in the microelement status 
in hemoglobinopathies [9]. Decrease in plasma iron in BTT patients 
as observed in the present study may be due to low ceruloplasmin 
that interferes in iron transport and utilization. Moreover, Babu et al. 
observed significant variation in complete hemogram in BTT patients 
compared to healthy individuals justifying our findings [16]. Iron-
zinc ratio doubled in BTT patients compared to normal signifying the 
importance of ratios in assessing the trace element status in these 
patients. In RBC, free iron is most likely redox active element that leads 
to the production of hydroxyl radical which  initiates membrane lipid 
peroxidation and protein oxidation thereby hemolysis. On aerobic 
incubation of RBCs, release of free iron was greater in BTT patients 
than controls [17]. High levels of HbF in BTT patients correlated with 
iron release, suggesting that persistence of HbF favors iron release and 
excess alpha chains act as prooxidants [18]. Moreover, trace elements 
(iron and copper) correlated positively with Hbs (A1 and A2) and a 
negatively with HbF in BTT patients. On the contrary, earlier reports 
showed no correlation between the iron state and the hemoglobin 
levels in beta-thalassemia trait subjects [19].
The study highlights marked deficiency of plasma trace elements, 
hence, the need for periodic assessment and prompt administration of 
these micronutrients to reduce the complications in BTT patients.
AUTHORS’ CONTRIBUTION
Prabhakaran: Biochemical analysis, Dr. Sudha K: Study design and 
manuscript preparation, Dr. Reshma K: Manuscript revision, and 
Mr.Durgarao: Statistical analysis.
CONFLICTS OF INTEREST
There are no conflicts of interest among the authors.
REFERENCES
1. Grow K, Vashist M, Abrol P, Ritu Y. Beta thalassemia in India: Current 
status and the challenges ahead. Int J Pharm Pharm Sci 2014;6:28-33.
2. Shamshirsaz AA, Bekheirnia MR, Kamgar M. Metabolic and 
endocrinologic complications in beta-thalassemia major: A multicenter 
study in Tehran. BMC Endocrine Disorders 2003;3:658-63.
3. Prasad AS. Zinc in human health: Effect of zinc on immune cells. Mol 
Med 2008;14:353-7.
4. Prakash M, Shetty J. A modified spectrophotometric micro method to 
determine serum copper. Asian J Biochem 2008;3:38-42.
5. Eva H, Suderman W. An accurate spectrophotometric method for 
serum iron and iron binding capacity without deproteinization or 
centrifugation. Ann Clin Lab Sci 1974;4:87-95.
6. Kalman S, Atay A, Sakallioglu O, Ozqurtas T, Gok F, Ismail K, 
et al. Renal tubular function in children with beta thalassemia minor. 
Nephrology 2005;10:427-9.
7. Kamal M, Talal A, Moussa B, Hamzeh N. Copper and zinc status in 
Jordanian patients with β-thalassemia major treated with deferoxamine. 
Res J Biol Sci 2009;4:566-72.
8. Mansi KI. Status of thyroid function and iron overload in adolescents and 
young adults with beta- thalassemia major treated with deferoxamine in 
Jordan. Proc World Acad Sci Eng Technol 2009;58:658-63.
9. Dangi CB, Manpreet K, Singh M. Copper and zinc quotient in 
haemoglobinopathies. Biomed Pharmacol J 2011;4:165-73.
10. Mahyar A, Ayazi P, Pahlevan AA, Mojabi H, Sehhat MR, Javadi A. 
Zinc and copper status in children with beta-thalassemia major. Iran J 
Pediatr 2010;20:297-302.
11. Al-Samarrai AH, Adaay MH, Al-Tikriti KA, Al-Anzy MM. Evaluation 
of some essential element levels in thalassemia major patients in Mosul 
district, Iraq. Saudi Med J 2008;29:94-7.
12. Ramdas M, Manpreet K, Ahmed A, Dangi CB. Trace elements ratio 
in patients of haemoglobinopathies. Int J Curr Microbiol App Sci 
2014;3:81-92.
13. Suthipark KU, Likidillid A, Fucharoen S, Pootrakul P, 
Shumnumsirivath D, Ong-ajyooth S, et al. Red cell and plasma calcium, 
copper and zinc in beta thalassemia/hemoglobin E. Southeast Asian J 
Trop Med Public Health 1991;22:171-5.
14. Filiz S, Gulyuz O, Sabri K, Deniz E, Alev H. Oxidant and antioxidant 
status in beta thalassemia major patients. J Ankara Univ Fac Med 
2005;58:34-8.
15. Bao B, Prasad AS, Beck FW, Snell D, Suneja A, Sarkar FH, et al. Zinc 
supplementation decreases oxidative stress, incidence of infection, and 
generation of inflammatory cytokines in sickle cell disease patients. 
Transl Res 2008;152:67-80.
Table 1: Comparison of hemoglobin levels in BTT patients and 
normal controls
Parameter Normal(n=20) BTT(n=40) p value
HbA1 (g %) 96.36±1.3 90.90±2.28 <0.001
HbA2 (g %) 2.94±0.24 5.27±0.24 <0.001
HbF (g %) 0.73±0.49 1.49±1.26 0.081
n: Number of samples. BTT: Beta-thalassemia trait, Hb: Hemoglobin
Table 2: Comparison of plasma trace elements in normal and 
BTT
Parameter Normal(n=20) BTT(n=40) p value
Copper (µg/dl) 96.41±13.66 85.66±14.77 0.04
Zinc (µg/dl) 83±5 40±9 <0.001
Copper: zinc 1.16±0.21 2.34±0.84 <0.001
Iron (µg/dl) 74.07±10.6 62.64±28.8 0.26
Iron: copper 0.77±0.13 0.72±0.05 0.17
Iron: zinc 0.89±0.11 1.56±0.27 0.001
n: Number of samples. BTT: Beta-thalassemia trait
Table 3: Correlation of trace elements with hemoglobins in BTT
Cu Zn Fe
r p r p r p
HbA1 0.18 0.29 −0.45 0.79 0.68 0.09
HbA2 0.05 0.73 −0.01 0.95 0.06 0.88
HbF −0.20 0.43 −0.84 0.75 −0.76 0.13
BTT: Beta-thalassemia trait, Hb: Hemoglobin
234
Asian J Pharm Clin Res, Vol 12, Issue 1, 2019, 232-234
 Prabhakaran et al. 
16. Babu S, Ashwini SS, Manjula S. Premarital screening of beta 
thalassemia trait in Dakshina Kannada population of Karnataka. Int J 
Pharm Pharm Sci 2016;9:268-72.
17. Ciccoli L, Signorini C, Scarano C, Rossi V, Bambagioni S, Ferrali M, 
et al. Iron release in erythrocytes from patients with beta-thalassemia. 
Free Radic Res 1999;30:407-13.
18. Comporti M, Signorini C, Buonocore G, Ciccoli L. Iron release, 
oxidative stress and erythrocyte ageing. Free Radic Biol Med 
2002;32:568-6.
19. da Fonseca SF, Kimura EY, Kerbauy J. Assessment of iron status in 
individuals with heterozygotic beta-thalassemia. Rev Assoc Med Bras 
1995;41:203-6.
